Cargando…
Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
Although adoptive immunotherapy (AIT) is a novel emerging target treatment for non-small cell lung cancer (NSCLC), its actual efficacy remains controversial. In this meta-analysis, we aimed to evaluate the efficacy of AIT for NSCLC. We systematically searched PubMed, the Cochrane Library, EMBASE, Me...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762575/ https://www.ncbi.nlm.nih.gov/pubmed/29348890 http://dx.doi.org/10.18632/oncotarget.19373 |
_version_ | 1783291713778876416 |
---|---|
author | Zhao, Binghao Zhang, Wenxiong Yu, Dongliang Xu, Jianjun Wei, Yiping |
author_facet | Zhao, Binghao Zhang, Wenxiong Yu, Dongliang Xu, Jianjun Wei, Yiping |
author_sort | Zhao, Binghao |
collection | PubMed |
description | Although adoptive immunotherapy (AIT) is a novel emerging target treatment for non-small cell lung cancer (NSCLC), its actual efficacy remains controversial. In this meta-analysis, we aimed to evaluate the efficacy of AIT for NSCLC. We systematically searched PubMed, the Cochrane Library, EMBASE, Medline, and Web of Science for relevant parallel randomized controlled trials (RCTs) and high-quality observation studies of AIT without any language restrictions. Two investigators reviewed all the texts and extracted information regarding overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), and disease control rate (DCR) from eligible studies; sensitivity analyses and subgroup analyses were also conducted to reduce heterogeneity Of 319 suitable studies, 15 studies (13 RCTs and 2 observation studies) involving 1684 patients were finally included. Compared to the Control therapy (CT) group, the AIT group exhibited better 1-year OS (P = 0.001), 2-year OS (P < 0.001), 3-year OS (P < 0.001), 5-year OS (P = 0.032), 1-year PFS (P < 0.001), and 2-year PFS (P = 0.029). The difference in the ORR (P = 0.293) and DCR (P = 0.123) was not significant between the groups. The subgroup analysis showed that DC/CIK did more benefit to NSCLC patients than LAK and the cycles not associated with AIT efficacy. AIT can significantly improve the OS and PFS with acceptable toxicity for NSCLC. Nevertheless, further multicenter studies are needed to confirm our conclusion and determine which adoptive immunotherapy is associated with the greatest efficacy. |
format | Online Article Text |
id | pubmed-5762575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57625752018-01-18 Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis Zhao, Binghao Zhang, Wenxiong Yu, Dongliang Xu, Jianjun Wei, Yiping Oncotarget Meta-Analysis Although adoptive immunotherapy (AIT) is a novel emerging target treatment for non-small cell lung cancer (NSCLC), its actual efficacy remains controversial. In this meta-analysis, we aimed to evaluate the efficacy of AIT for NSCLC. We systematically searched PubMed, the Cochrane Library, EMBASE, Medline, and Web of Science for relevant parallel randomized controlled trials (RCTs) and high-quality observation studies of AIT without any language restrictions. Two investigators reviewed all the texts and extracted information regarding overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), and disease control rate (DCR) from eligible studies; sensitivity analyses and subgroup analyses were also conducted to reduce heterogeneity Of 319 suitable studies, 15 studies (13 RCTs and 2 observation studies) involving 1684 patients were finally included. Compared to the Control therapy (CT) group, the AIT group exhibited better 1-year OS (P = 0.001), 2-year OS (P < 0.001), 3-year OS (P < 0.001), 5-year OS (P = 0.032), 1-year PFS (P < 0.001), and 2-year PFS (P = 0.029). The difference in the ORR (P = 0.293) and DCR (P = 0.123) was not significant between the groups. The subgroup analysis showed that DC/CIK did more benefit to NSCLC patients than LAK and the cycles not associated with AIT efficacy. AIT can significantly improve the OS and PFS with acceptable toxicity for NSCLC. Nevertheless, further multicenter studies are needed to confirm our conclusion and determine which adoptive immunotherapy is associated with the greatest efficacy. Impact Journals LLC 2017-07-19 /pmc/articles/PMC5762575/ /pubmed/29348890 http://dx.doi.org/10.18632/oncotarget.19373 Text en Copyright: © 2017 Zhao et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Meta-Analysis Zhao, Binghao Zhang, Wenxiong Yu, Dongliang Xu, Jianjun Wei, Yiping Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis |
title | Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis |
title_full | Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis |
title_fullStr | Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis |
title_full_unstemmed | Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis |
title_short | Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis |
title_sort | adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762575/ https://www.ncbi.nlm.nih.gov/pubmed/29348890 http://dx.doi.org/10.18632/oncotarget.19373 |
work_keys_str_mv | AT zhaobinghao adoptiveimmunotherapyshowsencouragingbenefitonnonsmallcelllungcancerasystematicreviewandmetaanalysis AT zhangwenxiong adoptiveimmunotherapyshowsencouragingbenefitonnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yudongliang adoptiveimmunotherapyshowsencouragingbenefitonnonsmallcelllungcancerasystematicreviewandmetaanalysis AT xujianjun adoptiveimmunotherapyshowsencouragingbenefitonnonsmallcelllungcancerasystematicreviewandmetaanalysis AT weiyiping adoptiveimmunotherapyshowsencouragingbenefitonnonsmallcelllungcancerasystematicreviewandmetaanalysis |